Yale Ventures’ newly surfaced FY2026 Annual Report shows $6 million in translational funding, 11 new faculty-led spinouts, and 73 new licenses/deals during the year. The funding is distributed across a growing portfolio of targeted accelerator funds: the Blavatnik Fund awarded $4.1 million across 21 projects, the Roberts Innovation Fund deployed $1 million across 10 projects, the new Planetary Solutions Impact Accelerator awarded $1 million across four projects, and HealthTech Works is preparing its first funding cycle.
The report also documents a substantial corporate-engagement layer: Yale says its Corporate Strategy & Engagement office raised $18 million for faculty research and programs, supported more than 100 active projects, and expanded relationships with companies including AstraZeneca, Boehringer Ingelheim, Unilever, NVIDIA, D-Wave and Quantinuum
